NASDAQ:BCRX

Biocryst Pharmaceuticals Stock Predictions

etoro logo Buy BCRX
*Your capital is at risk
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
Currently predicting for Thu, 4 Jun 2026

BCRX Prediction Chart

BCRX Predictions History

Latest community submissions for BCRX.
Predictor Target Session Target Price Result Direction Accuracy Score
Eli Galka Eli Galka @EliGalka.198076
Feb 3, 2021 $10.53 +2.23% $10.30 X 97.77% 1
JS JS Pro
Jan 25, 2021 $9.30 +1.53% $9.16 X 98.47% 0
Murali Prabhu Murali Prabhu @MuraliPrabhu.187846
Jan 25, 2021 $6.00 -34.50% $9.16 X 65.50% 1
JS JS Pro
Dec 21, 2020 $8.78 +5.78% $8.30 X 94.22% 0
Alan Alan Pro @Alan.115878
Dec 21, 2020 $8.80 +6.02% $8.30 X 93.98% 0
JS JS Pro
Nov 30, 2020 $4.94 -3.33% $5.11 X 96.67% 1
Alan Alan Pro @Alan.115878
Nov 30, 2020 $5.08 -0.59% $5.11 X 99.41% 4
JS JS Pro
Jul 13, 2020 $5.34 +7.88% $4.95 X 92.12% 1
JS JS Pro
Jun 22, 2020 $3.71 -9.95% $4.12 X 90.05% 0
Jun 22, 2020 Bearish $4.12 X 0
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for BCRX with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT BIOCRYST PHARMACEUTICALS
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE